Product Approval / Market Expansion
Aurobindo Pharma Receives USFDA Approval for Dextromethorphan Polistirex Oral Suspension (OTC)
NSE
auropharma
BSE
524804
Aurobindo Pharma has received final USFDA approval for Dextromethorphan Polistirex Extended-Release Oral Suspension, 30 mg/5 mL (OTC), with launch planned in Q2FY27, expanding its US product portfolio and strengthening its OTC presence.
PRICE-SENSITIVE TRIGGER
Event: USFDA Final Product Approval
Type: Product Approval / Market Expansion
Impact: Positive
Immediate Effect: Expands commercial opportunity in the US and supports future revenue growth
Financial Snapshot
- Product: Dextromethorphan Polistirex Extended-Release Oral Suspension (OTC)
- Reference Product: Delsym Extended-Release Oral Suspension
- Estimated Market Size: US$138 Million (12 months ended Feb 2026)
- Total USFDA ANDA Approvals: 580
- Final Approvals: 557
- Tentative Approvals: 23
Highlight:
Entry into a US$138 million market opportunity with approved OTC respiratory product
What Happened ?
Aurobindo Pharma announced receipt of final approval from the USFDA to manufacture and market Dextromethorphan Polistirex Extended-Release Oral Suspension, 30 mg/5 mL (OTC).
The product is bioequivalent and therapeutically equivalent to the reference listed drug Delsym and will be manufactured at Unit-IV of APL Healthcare Limited, a wholly owned subsidiary.
Commercial launch is planned in Q2FY27.
key highlights
Product Approval:
- Final USFDA approval received
- OTC cough suppressant product
- Equivalent to Delsym (RLD)
Market Opportunity:
- Estimated addressable market: US$138 million
- Strengthens US OTC portfolio
Manufacturing & Launch:
- To be manufactured at Unit-IV facility
- Launch targeted in Q2FY27
Strategic Significance:
- Expands US generics/OTC portfolio
- Reinforces strength in regulated markets
- Adds to broad ANDA approvals pipeline
Risk Analysis
Key Risks
- Delays in product launch timeline
- Pricing pressure in US generics/OTC markets
- Lower-than-expected market share capture
- Competitive pressure from existing players
Worst Case Scenario
Approval does not translate into meaningful commercial contribution due to pricing or competitive pressures
Risk Level: Low
Company Commentary
- Expanding US product portfolio
- Strengthening OTC market presence
- Continuing growth through robust ANDA pipeline
- Focus on commercialization in Q2FY27
Official Exchange Filing: Aurobindo Pharma Limited